A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
← catalyst calendarNCT06644781 · readout in 652 d
Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
510estimated
Sites
132
Countries
Belgium, China, Denmark +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-27 | actual | When the study began enrolling |
| Primary completion | 2028-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-11-01 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Esophageal Squamous Cell Carcinoma
Interventions
- Drug: Ifinatamab deruxtecan — also filed as I-DXd
- Drug: Docetaxel
- Drug: Paclitaxel
- Drug: Irinotecan hydrochloride (HCl)
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured From the date of randomization to the date of death due to any cause, up to approximately 54 months
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed